Publication | Open Access

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

MedicinePharmacologyImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentPhase 2OncologyRadiation OncologyCypress 2Molecular OncologyCheckpoint Inhibitors Alone